RxDoctor Payments Data

Sayyah Ajlouni, MD

Cardiovascular Disease · Miamisburg, OHNPI 1003980186

Payments from drug & device makers

$1,926in general payments, 2019–2025

Across 94 payments — averaging $20.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$508
  • Pfizer$343
  • Novo Nordisk$319
  • Johnson & Johnson$229
  • Boehringer Ingelheim$210
  • Amgen$151
  • plus $167 from 4 others

What the payments were for

  • Food & beverage$1,68687%
  • Education$24113%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,926 in reported general payments places this provider in the 50th percentile of 827 cardiovascular disease providers in Ohio.

See all cardiovascular disease providers in Ohio

Medicare billing

Part B allowed, 2024
$98,291
Medicare patients
85
Services billed
902

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban53$39,851
JardianceEmpagliflozin21$17,388
Lantus SolostarInsulin Glargine,hum.Rec.Anlog12$1,835
Isosorbide Dinitrate21$1,797
Albuterol Sulfate HfaAlbuterol Sulfate91$1,580
Atorvastatin Calcium168$1,333
Isosorbide Mononitrate ErIsosorbide Mononitrate92$1,278
Omeprazole123$1,205
Potassium Chloride86$1,001
Klor-Con M20Potassium Chloride17$896
Losartan Potassium144$829
Metoprolol Succinate38$823
Furosemide235$782
Pantoprazole Sodium103$768
Ventolin HfaAlbuterol Sulfate14$766

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$343$39,85153 claims
Boehringer IngelheimJardiance$210$17,38821 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 827 cardiovascular disease providers in Ohio.

Other cardiovascular disease in Miamisburg

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →